Evofem Biosciences Statistics
Total Valuation
Evofem Biosciences has a market cap or net worth of 1.03 million. The enterprise value is 50.37 million.
| Market Cap | 1.03M |
| Enterprise Value | 50.37M |
Important Dates
The next estimated earnings date is Monday, March 3, 2025.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evofem Biosciences has 113.36 million shares outstanding. The number of shares has decreased by -90.09% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 113.36M |
| Shares Change (YoY) | -90.09% |
| Shares Change (QoQ) | -94.02% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.09% |
| Float | 113.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.03 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.57 |
| EV / Sales | 2.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.32 |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -26.96 |
| Interest Coverage | -3.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.72% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 449,947 |
| Profits Per Employee | -290,000 |
| Employee Count | 38 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.64 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.18% in the last 52 weeks. The beta is -0.69, so Evofem Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | -0.69 |
| 52-Week Price Change | -86.18% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 41.20 |
| Average Volume (20 Days) | 392,229 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, Evofem Biosciences had revenue of 17.10 million and -11.02 million in losses. Loss per share was -0.28.
| Revenue | 17.10M |
| Gross Profit | 13.82M |
| Operating Income | -10.05M |
| Pretax Income | -7.94M |
| Net Income | -11.02M |
| EBITDA | -9.71M |
| EBIT | -10.05M |
| Loss Per Share | -0.28 |
Balance Sheet
The company has 202,000 in cash and 44.78 million in debt, giving a net cash position of -44.58 million or -0.39 per share.
| Cash & Cash Equivalents | 202,000 |
| Total Debt | 44.78M |
| Net Cash | -44.58M |
| Net Cash Per Share | -0.39 |
| Equity (Book Value) | -66.13M |
| Book Value Per Share | -0.71 |
| Working Capital | -67.71M |
Cash Flow
In the last 12 months, operating cash flow was -1.65 million and capital expenditures -14,000, giving a free cash flow of -1.66 million.
| Operating Cash Flow | -1.65M |
| Capital Expenditures | -14,000 |
| Free Cash Flow | -1.66M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 80.84%, with operating and profit margins of -58.80% and -46.42%.
| Gross Margin | 80.84% |
| Operating Margin | -58.80% |
| Pretax Margin | -46.42% |
| Profit Margin | -46.42% |
| EBITDA Margin | -56.76% |
| EBIT Margin | -58.80% |
| FCF Margin | n/a |
Dividends & Yields
Evofem Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 90.09% |
| Shareholder Yield | 90.09% |
| Earnings Yield | -3,049.81% |
| FCF Yield | -161.02% |
Stock Splits
The last stock split was on May 18, 2023. It was a reverse split with a ratio of 0.008.
| Last Split Date | May 18, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.008 |
Scores
Evofem Biosciences has an Altman Z-Score of -56.37. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -56.37 |
| Piotroski F-Score | n/a |